SLXNW — Silexion Therapeutics Ltd.
$0.0099-1.00%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SLXNW in the TickerWise workspace.
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 11
- Website: https://silexion.com
Latest SEC filings for SLXNW
- SCHEDULE 13D/A
- SCHEDULE 13D/A
- SCHEDULE 13G
- SCHEDULE 13G/A
- EFFECT
- S-1/A
- SCHEDULE 13D/A
- EFFECT
- 10-K/A
- EFFECT
Latest SLXNW news
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.